BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S today announced that Birgitta Stymne Göransson has been elected member of the company’s Board of Directors.
Birgitta Stymne Göransson has worked as non-executive Boardmember, Chairman and Committee Chair of several boards and audit committees and has more than 25 years of experience in medtech and IT/tech as well as consulting, consumer retail and branded goods.
Birgitta Stymne Göransson’s current chairmanships include BCB Medical Oy and Industrifonden in Sweden as well as Chair of the Audit Committees of Elekta AB and Pandora AS. In her previous executive roles, she has among other worked as Industrial Advisor to Ratos AB, and held positions as Chief Executive at Memira Holding AB and Semantix Group AB.
Olivier Bohuon, Chairman of the Board of Directors at LEO Pharma A/S, says: “We are pleased to welcome Birgitta Stymne Göransson to the Board of Directors. With her broad industry insights and deep financial experience from both public and private companies, she will play an important role in the realization of LEO Pharma’s ambitious growth strategy.”
Birgitta Stymne Göransson holds an MBA from Harvard Business School, MA, USA as well as a M.Sc. in Chemical Engineering and Biotechnology from the Royal Institute of Technology in Sweden.
- Ends –
About LEO Pharma A/S
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit.
Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.